Chaperone-Like Therapy with Tetrahydrobiopterin in Clinical Trials for Phenylketonuria: Is Genotype a Predictor of Response?

  • Christineh N. Sarkissian
  • Alejandra Gamez
  • Patrick Scott
  • Jerome Dauvillier
  • Alejandro Dorenbaum
  • Charles R. Scriver
  • Raymond C. Stevens
Research Report
Part of the JIMD Reports book series (JIMD, volume 5)

Abstract

Prospectively enrolled phenylketonuria patients (n=485) participated in an international Phase II clinical trial to identify the prevalence of a therapeutic response to daily doses of sapropterin dihydrochloride (sapropterin, KUVAN®). Responsive patients were then enrolled in two subsequent Phase III clinical trials to examine safety, ability to reduce blood Phenylalanine levels, dosage (5–20 mg/kg/day) and response, and bioavailability of sapropterin. We combined phenotypic findings in the Phase II and III clinical trials to classify study-related responsiveness associated with specific alleles and genotypes identified in the patients. We found that 17% of patients showed a response to sapropterin. The patients harbored 245 different genotypes derived from 122 different alleles, among which ten alleles were newly discovered. Only 16.3% of the genotypes clearly conferred a sapropterin-responsive phenotype. Among the different PAH alleles, only 5% conferred a responsive phenotype. The responsive alleles were largely but not solely missense mutations known to or likely to cause misfolding of the PAH subunit. However, the metabolic response was not robustly predictable from the PAH genotypes, based on the study design adopted for these clinical trials, and accordingly it seems prudent to test each person for this phenotype with a standardized protocol.

Notes

Acknowledgements

We are indebted to the PKU patients and families who enrolled this study, as well as doctors and their healthcare staff for their invaluable assistance in the conduct of the clinical studies. We also thank our colleagues, John Tomaro for data collection, Sonia Schnieper-Samec for help with statistical review, Kumar Saikatendu and Katya Kadyshevskaya for the 3D figure preparation, Angela Walker for assistance with manuscript preparation and submission to the journal, Sun Sook Kim and Sabrina Cheng for data revision, and Manyphong Phommarinh and Jacques Mao for assistance with PAHdb. A. Gamez was supported by a research contract from “Ramón y Cajal” program by Ministerio de Ciencia e Innovación and Fundación Ramón Areces.

Supplementary material

Suppl table 1.xls (130 KB)

Suppl table 2.doc (18 KB)

Suppl table 2.doc (98 KB)

References

  1. Bechtluft P, van Leeuwen RG, Tyreman M et al (2007) Direct observation of chaperone-induced changes in a protein folding pathway. Science 318(5855):1458–1461PubMedCrossRefGoogle Scholar
  2. Bernegger C, Blau N (2002) High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol Genet Metab 77(4):304–313PubMedCrossRefGoogle Scholar
  3. Blau N, Trefz FK (2002) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency: possible regulation of gene expression in a patient with the homozygous L48S mutation. Mol Genet Metab 75(2):186–187PubMedCrossRefGoogle Scholar
  4. Blau N, Bélanger-Quintana A, Demirkol M et al (2009) Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab 96(4):158–163PubMedCrossRefGoogle Scholar
  5. Burgard P, Bremer HJ, Buhrdel P et al (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 158(1):46–54PubMedCrossRefGoogle Scholar
  6. Burton BK, Grange DK, Milanowski A et al (2007) The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): A phase II, multicentre, open-label, screening study. J Inherit Metab Dis 30(5):700–707PubMedCrossRefGoogle Scholar
  7. Burton BK, Bausell H, Katz R, Laduca H, Sullivan C (2010) Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol Genet Metab 101(2–3):110–114PubMedCrossRefGoogle Scholar
  8. Desviat LR, Perez B, Belanger-Quintana A et al (2004) Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab 83(1–2):157–162PubMedCrossRefGoogle Scholar
  9. Dobrowolski SF, Borski K, Ellingson CC, Koch R, Levy HL, Naylor EW (2009a) A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin. J Hum Genet 54(6):335–339PubMedCrossRefGoogle Scholar
  10. Dobrowolski SF, Pey AL, Koch R et al (2009b) Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients. J Inherit Metab Dis 32(1):10–21PubMedCrossRefGoogle Scholar
  11. Dobrowolski SF, Heintz C, Miller T et al (2011) Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population. Mol Genet Metab 102(2):116–121PubMedCrossRefGoogle Scholar
  12. Donlon J, Levy HL, Scriver CR (2010) Hyperphenylalanine: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW (eds) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York. Online. http://genetics.accessmedicine.com
  13. Elsas LJ, Greto J, Wierenga A (2011) The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria. Mol Genet Metab 102(4):407–412PubMedCrossRefGoogle Scholar
  14. Erlandsen H, Pey AL, Gamez A et al (2004) Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 101(48):16903–16908PubMedCrossRefGoogle Scholar
  15. Fiege B, Ballhausen D, Kierat L et al (2004) Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab 81(1):45–51PubMedCrossRefGoogle Scholar
  16. Fiori L, Fiege B, Riva E, Giovannini M (2005) Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients. Mol Genet Metab 86(S1):S67–74PubMedCrossRefGoogle Scholar
  17. Guldberg P, Rey F, Zschocke J et al (1998) A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63(1):71–79PubMedCrossRefGoogle Scholar
  18. Hennermann JB, Buhrer C, Blau N, Vetter B, Monch E (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 86(S1):S86–90PubMedCrossRefGoogle Scholar
  19. Karacić I, Meili D, Sarnavka V et al (2009) Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab 97(3):165–171PubMedCrossRefGoogle Scholar
  20. Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR (1997) Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet 61(6):1309–1317PubMedCrossRefGoogle Scholar
  21. Kure S, Hou DC, Ohura T et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135(3):375–378PubMedCrossRefGoogle Scholar
  22. Kure S, Sato K, Fujii K et al (2004) Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 83(1–2):150–156PubMedCrossRefGoogle Scholar
  23. Langenbeck U (2008) Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias. J Inherit Metab Dis 31(1):67–72PubMedCrossRefGoogle Scholar
  24. Lee P, Treacy EP, Crombez E et al (2008) Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A 146A(22):2851–2859PubMedCrossRefGoogle Scholar
  25. Leuzzi V, Carducci C, Chiarotti F, Artiola C, Giovanniello T, Antonozzi I (2006) The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. J Inherit Metab Dis 29(1):38–46PubMedCrossRefGoogle Scholar
  26. Levy HL, Milanowski A, Chakrapani A et al (2007) Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370(9586):504–510PubMedCrossRefGoogle Scholar
  27. Lindner M, Haas D, Mayatepek E, Zschocke J, Burgard P (2001) Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol Genet Metab 73(1):104–106PubMedCrossRefGoogle Scholar
  28. Lindner M, Steinfeld R, Burgard P, Schulze A, Mayatepek E, Zschocke J (2003) Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 21(4):400PubMedCrossRefGoogle Scholar
  29. Matalon R, Koch R, Michals-Matalon K et al (2004) Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 6(1):27–32PubMedCrossRefGoogle Scholar
  30. Muntau AC, Roschinger W, Habich M et al (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347(26):2122–2132PubMedCrossRefGoogle Scholar
  31. Nielsen JB, Nielsen KE, Güttler F (2010) Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. J Inherit Metab Dis 33(1):9–16PubMedCrossRefGoogle Scholar
  32. Okano Y, Eisensmith RC, Guttler F et al (1991) Molecular basis of phenotypic heterogeneity in phenylketonuria. N Engl J Med 324(18):1232–1238PubMedCrossRefGoogle Scholar
  33. Panel NIoHCD (2001) National Institutes of Health Consensus Development conference statement: Phenylketonuria: screening and management. Pediatrics 10:972–982Google Scholar
  34. Pey AL, Perez B, Desviat LR et al (2004) Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat 24(5):388–399PubMedCrossRefGoogle Scholar
  35. Pey AL, Stricher F, Serrano L, Martinez A (2007) Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet 81(5):1006–1024PubMedCrossRefGoogle Scholar
  36. Phenylketonuria MRCWPo (1993) Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Br Med J 306(6870):115–119CrossRefGoogle Scholar
  37. Scavelli R, Ding Z, Blau N, Haavik J, Martinez A, Thony B (2005) Stimulation of hepatic phenylalanine hydroxylase activity but not Pah-mRNA expression upon oral loading of tetrahydrobiopterin in normal mice. Mol Genet Metab 86(S1):S153–155PubMedCrossRefGoogle Scholar
  38. Scriver CR (1991) Phenylketonuria – genotypes and phenotypes. N Engl J Med 324(18):1280–1281PubMedCrossRefGoogle Scholar
  39. Scriver CR (2007) The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 28(9):831–845PubMedCrossRefGoogle Scholar
  40. Scriver CR, Clow CL (1980a) Phenylketonuria: epitome of human biochemical genetics (first of two parts). N Engl J Med 303(23):1336–1342PubMedCrossRefGoogle Scholar
  41. Scriver CR, Clow CL (1980b) Phenylketonuria: epitome of human biochemical genetics (second of two parts). N Engl J Med 303(24):1394–1400PubMedCrossRefGoogle Scholar
  42. Scriver CR, Waters PJ (1999) Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet 15(7):267–272PubMedCrossRefGoogle Scholar
  43. Shintaku H, Fujioka H, Sawada Y, Asada M, Yamano T (2005) Plasma biopterin levels and tetrahydrobiopterin responsiveness. Mol Genet Metab 86(S1):S104–106PubMedCrossRefGoogle Scholar
  44. Spaapen LJ, Rubio-Gozalbo ME (2003) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art. Mol Genet Metab 78(2):93–99PubMedCrossRefGoogle Scholar
  45. Thony B, Blau N (2006) Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 27(9):870–878PubMedCrossRefGoogle Scholar
  46. Trefz FK, Aulela-Scholz C, Blau N (2001) Successful treatment of phenylketonuria with tetrahydrobiopterin. Eur J Pediatr 160(5):315PubMedCrossRefGoogle Scholar
  47. Trefz FK, Burton BK, Longo N et al (2009a) Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 154(5):700–707PubMedCrossRefGoogle Scholar
  48. Trefz FK, Scheible D, Götz H, Frauendienst-Egger G (2009b) Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J Inherit Metab Dis 32(1):22–26PubMedCrossRefGoogle Scholar
  49. Trefz FK, Scheible D, Frauendienst-Egger G (2010) Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment. J Inherit Metab Dis Mar 9 EpubGoogle Scholar
  50. Waters PJ, Parniak MA, Akerman BR, Jones AO, Scriver CR (1999) Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: a mechanism underlying phenylketonuria. J Inherit Metab Dis 22(3):208–212PubMedCrossRefGoogle Scholar
  51. Waters PJ, Parniak MA, Akerman BR, Scriver CR (2000) Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. Mol Genet Metab 69(2):101–110PubMedCrossRefGoogle Scholar
  52. Weglage J, Grenzebach M, von Teeffelen-Heithoff A et al (2002) Tetrahydrobiopterin responsiveness in a large series of phenylketonuria patients. J Inherit Metab Dis 25(4):321–322PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Christineh N. Sarkissian
    • 1
    • 2
  • Alejandra Gamez
    • 3
  • Patrick Scott
    • 1
  • Jerome Dauvillier
    • 4
  • Alejandro Dorenbaum
    • 5
  • Charles R. Scriver
    • 1
    • 2
  • Raymond C. Stevens
    • 6
  1. 1.Departments of Biology, Human Genetics and PediatricsMcGill UniversityMontrealCanada
  2. 2.Debelle LaboratoryMcGill University-Montreal Children’s Hospital Research InstituteMontrealCanada
  3. 3.Centro de Biología Molecular Severo Ochoa, Nicolas Cabrera 1 Laboratorio 204. Campus CantoblancoUniversidad Autónoma de MadridMadridSpain
  4. 4.Merck Serono S.AGenevaSwitzerland
  5. 5.BioMarin Pharmaceutical IncNovatoUSA
  6. 6.Department of Molecular BiologyThe Scripps Research InstituteLa JollaUSA

Personalised recommendations